🇺🇸 FDA

Intelligence · Patent portfolio

Alnylam Netherlands Patents

Full USPTO pharma patent portfolio for Alnylam Netherlands — grant dates, expiration, and drug cross-links.

Patents
379
Expiring ≤24m
4

Quick answer

Alnylam Netherlands has 379 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 8

  1. US 11633479

    Biodegradable lipids for the delivery of active agents

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11633480

    Biodegradable lipids for the delivery of active agents

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11612657

    Biodegradable lipids for the delivery of active agents

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11590229

    Biodegradable lipids for the delivery of active agents

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11549109

    Modified double-stranded RNA agents

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11530408

    Therapeutic compositions

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11525138

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11504391

    Modified RNA agents with reduced off-target effect

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11492623

    Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11446380

    Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11434487

    Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11427822

    Modified double-stranded RNA agents

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11419942

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11408001

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11406716

    Modified RNAi agents

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11401517

    Modified double-stranded RNA agents

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11400158

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11382979

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11332743

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11326166

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11324820

    Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11319539

    Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11312957

    Modified iRNA agents

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11306316

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11306315

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11306314

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11286482

    Endosomal cleavable linkers

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11286486

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11261447

    Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11246933

    Biodegradable lipids for the delivery of active agents

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11229663

    Serum amyloid P component (APCS) iRNA compositions and methods of use thereof

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11207342

    High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11198872

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11198876

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11186842

    Complement component iRNA compositions and methods of use thereof

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11162098

    Complement component C5 iRNA compositions and methods of use thereof

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11149273

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11149276

    Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11142766

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11136582

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11130953

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11110174

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11079379

    Methods of treating transthyretin (TTR) mediated amyloidosis

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11071784

    Biodegradable lipids for the delivery of active agents

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11066670

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11060091

    Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11053495

    Multi-targeted single entity conjugates

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11052103

    Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alnylam Netherlands have?

379 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alnylam Netherlands patents expire?

4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.